Extractions: Vol. 133 No. 6, June 1979 Featured Link E-mail Alerts ARTICLE Article Options Send to a Friend Readers Reply Submit a reply Similar articles in this journal Literature Track Add to File Drawer Download to Citation Manager Articles in PubMed by Collen RJ Kaplan SA Articles that cite this article Contact me when this article is cited R. J. Collen, B. M. Lippe and S. A. Kaplan A female adolescent with primary ovarian failure was found to have circulating autoantibodies to her ovaries. Primary ovarian failure in pediatrics is usually attributed to gonadal dysgenesis. Autoimmune oophoritis is a rare cause and is most often associated with Addison's disease and other autoimmune endocrinopathies. Our patient also had juvenile rheumatoid arthritis and vitiligo. To our knowledge, this case
Entrez PubMed Sixteen Korean female laborers who had been exposed to a cleaning solvent composed mainly of 2bromo http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9
Entrez PubMed Eightyone patients who had a diagnosis of primary ovarian failure were studied to determine its pos http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6
Obstetrical & Gynecological Survey - UserLogin and the Delay of Pubarche Indicate primary ovarian failure in Turner Syndrome in 22 of these girls, whereas 45 had primary ovarian failure (POF). http://www.obgynsurvey.com/pt/re/obgynsurv/fulltext.00006254-200412000-00011.htm
Extractions: Girls with Turner syndrome provide the first human model in which adrenal puberty (adrenarche) takes place without gonadal puberty. A wide range of serum dehydroepiandrosterone sulfate (DHEAS) concentrations has been observed, ranging from normal to very elevated. This study attempted to determine whether the course of adrenarche and pubarche is independent of ovarian function. A total of 867 serum DHEAS estimates were made over time in 111 girls with Turner syndrome. Puberty began spontaneously in 22 of these girls, whereas 45 had primary ovarian failure (POF). Serum DHEAS levels were compared with those of 322 healthy girls 3 to 17 years of age. POF was defined as a lack of spontaneous breast development and at least 1 follicle-stimulating hormone (FSH) level of 50 IU/L or higher before estrogen replacement therapy. Age-related serum concentrations of DHEAS were significantly higher in girls with Turner syndrome than in control girls from ages 7 to 17 years. Those with POF had significantly higher age-related levels than did girls experiencing spontaneous puberty at ages 9 to 15 years. Adrenarche occurred at a median age of 8.3 years in girls with POF, compared with 10.5 years for girls with spontaneous puberty and 11 years in normal girls. In both groups with Turner syndrome, mean DHEAS levels correlated closely with mean FSH and luteinizing hormone levels. Pubarche was delayed in girls with POF despite their high serum DHEAS levels. Puberty occurred more than 4.5 years after adrenarche, at a median age of 13 years, in girls with Turner syndrome, whereas in girls with spontaneous puberty, the interval was 1.4 years and the median age at pubarche was 11.9 years.
Estrogen Therapy Patch Comparison - VivelleDot.com hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; and for the prevention of postmenopausal osteoporosis (loss of bone mass). http://www.vivelledot.com/eng_pro/patch_comparison.cfm
Extractions: Estraderm (estradiol transdermal system) is indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; atrophic vaginitis and kraurosis vulvae, atrophic urethritis, hypoestrogenism due to hypogonadism, castration, or primary ovarian failure; and for the prevention of postmenopausal osteoporosis (loss of bone mass).
Extractions: Low thyroid function and an elevated day 3 FSH. What does it mean? Q . Your discussion of Autoimmune Oophoritis (in Overcoming Infertility) piqued my interest because I was just diagnosed with slight hypothyroidism for which I am taking Synthroid. I will be undergoing new day 3 FSH levels in a couple of weeks after having been on the medication for the last month, in the hope that my FSH levels are back to normal or at least below 10. I do not have painful enlargement of the ovaries, but I gather that autoimmune oophoritis might not show up as the painful enlargement of the ovaries until all the follicles have been burned out. You say that tissue antibodies such as thyroid antibodies are looked for, however they are rarely present. What I can't figure out is, if thyroid antibodies are present (like with me) and the ovaries aren't enlarged, and the thyroid problem is corrected, what happens? Can some good follicles be left? If so, if FSH levels start looking good again is there some hope? There are real connections between an underactive thyroid and problems with ovulation. But neither thyroid disease nor primary ovarian failure is rare. In practice, the association is often a coincidence.
Overcoming Infertility primary ovarian failure. Failure of the ovaries to produce enough follicles, because of a problem in the ovary itself, and resulting in depletion of eggs http://www.jansen.com.au/silver/glossary.asp?keyword=primary ovarian failure
Extractions: What's it all about? The doctor is usually both an obstetrician and a gynaecologist, although some have special interests and some sub-specialise further. There are overlaps between the two subjects, but essentially obstetrics is the science of pregnancy, and gynaecology is female reproductive medicine. In the course of obstetrics and gynaecology, you might also cover sexual health more widely, areas such as male reproductive health and infertility. The practice of obstetrics and gynaecology includes outpatient clinics, inpatients, theatre, assisting with deliveries and possibly some postnatal and neonatal care.
ANZJM Vol. 30 No. 1 February 2000 - Editorials The prevalence of autoimmune disorders among patients with primary ovarian failure. Familial idiopathic premature ovarian failure an overrated and http://www.racp.edu.au/anzjm/fe00ed3.htm
Extractions: Email: a.shelling@auckland.ac.nz Two articles in this issue of the Journal by Driscoll et al. ) and McAuley et al ) describe patients with premature ovarian failure (POF) with associated defects on the X chromosome which offer insights into the aetiology of this complex disorder. POF is characterised by secondary amenorrhoea, hypoestrogenism, and elevated gonadotrophins in women under the age of 40 years. It is a common condition and occurs in 1% of women under the age of 40 years, and will affect 0.1% of women before the age of 30 years.( ) POF is becoming a challenging issue for couples, particularly as women delay having families until later in life. Two significant consequences of POF are the loss of fertility, and the clinical effects of hypoestrogenism. Low levels of oestrogen from a young age appear to increase the risk of osteoporosis and coronary heart disease.( POF is clearly a heterogeneous disorder, and only a few causes can be identified.(
Cancer Chemotherapy And Fertility is the major cause of amenorrhea, which is due to primary ovarian failure. In ovarian failure or menopause, the ovary is depleted of all follicles, http://www.cancernews.com/articles/cancer&fertility.htm
Extractions: This article is provided for information purposes only. It is not intended to be used for medical advice. Please read Used by the permission of The Patient Resource Center Salick Health Care, Inc. Cancer News on the Net Breast Cancer in Young Women : Effect of Chemotherapy on Ovarian Function, Fertility, and Birth Defects Bonnie S. Reichman, Karen B. Green A comprehensive review of the literature was done to assess the effect of adjuvant chemotherapy for operable breast cancer on ovarian function, fertility, and birth defects. Data were limited. Cyclophosphamide, an alkylating agent, is the major cause of amenorrhea, which is due to primary ovarian failure. Ovarian dysfunction is related to age, dose, and duration of treatment. In women less than 35, pregnancy following adjuvant chemotherapy is possible. However, data are limited regarding the impact of subsequent pregnancy on the results of breast cancer. There appears to be no increased risk of teratogenesis in offspring exposed to chemotherapy after the first trimester of pregnancy. Prospective data on women who have subsequent pregnancies and their offspring are very limited. Formation of a registry for long-term follow-up of young women detailing reproductive potential and follow-up of offspring is needed. [Monogr Natl Cancer Inst 16:125-129, 1994] A single dominant follicle is selected by days 5-7 in the ovarian menstrual cycle, with ovulation of a fertilizable egg at day 14. All other follicles that were recruited in that cycle undergo atresia. As the dominant follicle emerges, there is increasing production of estrogen that stimulates the mid-cycle luteinizing hormone (LH) and follicle-stimulating hormone (FSH) surge. The abrupt rise in LH leads to meiotic maturation of the oocyte before ovulation, release of the oocyte by the ovulating process, and formation of the corpus luteum by luteinization of the granulosa and theca cells of the dominant follicle.
Faces Of POF: Preview Faces of POF Living and Learning with Premature Ovarian Failure. I was diagnosed with primary ovarian failure at age sixteen. http://www.pofsupport.org/facesofpof/preview.htm
Extractions: I was diagnosed with primary ovarian failure at age sixteen. I have lived with this diagnosis and have been on hormone replacement therapy for twenty-five years. I hope that my story might help others who have been diagnosed with this rare form of premature ovarian failure. I grew up as many girls did, looking forward to the time when I would be a mother to my own children. I would pretend to be pregnant with a pillow or dolly under my shirt. I also grew up in an atmosphere where marrying, being a mother, and raising children was a large part of who I would be. This was reinforced by my religious community. My parents raised me as early as age six with information about where babies came from and how they developed in a woman. As I grew older I learned about my body maturation. In seventh grade, I looked forward to the day I would have my first period along with my friends. Not working on having a child is still new to me. I still get twinges of disappointment and discomfort when I see other pregnant women, or when I see mothers holding their infants. I have felt less lonely in my situation as I have visited the POF support board on the Internet. I appreciate the opportunity of connection, learning, and helping others more like myself. I am learning to add a little bit more of what I love doing, still giving and sharing with others to fill my life. I have many questions to ask God when I leave this world. Until then, I choose to keep going and doing the best I can.
The Society For Endocrinology - Training to damage by chemotherapy or radiation, or to autoimmune disease. The main genetic disease causing primary ovarian failure is Turner syndrome (45XO). http://www.endocrinology.org/sfe/training/ent00/ent00_dav.htm
Extractions: St Annes's College, Oxford, UK Pituitary disease and hypothalamic disease each affect the normal patterns of production of gonadotrophins. Hyperprolactinaemia is the single commonest pituitary abnormality, and can result from pituitary adenomas, disruption of the pituitary stalk, and dopamine antagonist drugs, including phenothiazines, metoclopramide and domperidone. The effect of hyperprolactinaemia on women is most obvious because of abnormal lactation, but in both men and women excess prolactin suppresses the normal pulsatile release of GnRH from the hypothalamus and the gonadotrophins LH and FSH from the pituitary. The result in women is loss of the ovarian cyclical production of both mature oocytes and oestrogen, and in men, suppression of testosterone secretion and oligospermia, with loss of libido in both sexes. Most other types of pituitary disease readily affect gonadotrophin production. Any destructive lesions of the pituitary or hypothalamus interfere with the normal pulsatile production of LH and FSH, and even if hormone levels remain within the reference range for a single sample, it is the disrupted pattern of secretion that is critical, resulting in a complete lack of gonadal response. Pituitary tumours, including Cushing's disease, acromegaly and non-functioning adenomas, may all have this effect, depending on the size and location of the tumour. Pituitary surgery, even selective microadenomectomy, carries a risk of damaging gonadotroph function, and radiotherapy ultimately causes progressive pituitary and hypothalamic damage resulting in gonadal dysfunction.
Eye & Contact Lens: Science And Clinical Practice - UserLogin primary ovarian failure, multiple thrombotic cerebrovascular accidents, Ovarian failure was documented through an endocrine workup that showed http://www.claojournal.org/pt/re/eclens/fulltext.00140068-200310000-00018.htm
Extractions: Search for: Limit by: All Topics Original Reports Review Articles Special Articles Biology of Neoplasia Editorials Comments and Controversies Diagnosis in Oncology Art of Oncology Correspondence All Years Browse by Topic or Issue Home Search/Browse Subscriptions ... Customer Service This Article Abstract Full Text (PDF) Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal ... Cited by other online articles PubMed PubMed Citation Articles by Shapiro, C. L. Articles by Leboff, M. Journal of Clinical Oncology , Vol 19, Issue 14 (July), 2001: 3306-3311 American Society for Clinical Oncology By Charles L. Shapiro Judith Manola Meryl Leboff Address reprint requests to Charles L. Shapiro, MD, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University, Starling-Loving Hall B421, 320 West 10th Ave, Columbus, OH 43210; email:
060101 - Bone Density Studies Other ovarian failure (ovarian hypofunction, primary ovarian failure). 259.3. Ectopic hormone secretion, not elsewhere specified http://www.empireblue.com/medical_policies_short/radiology/bone_density_studies.
Extractions: Definition Bone mineral density (BMD) measurement is a non-invasive technique that is used to measure bone mineral content and bone mineral density. Its primary role is to detect osteoporosis and to predict the risk of fractures. There are several techniques, which are currently used to measure bone mass. These include single- and dual- absorptiometry, quantitative computed tomography, and ultrasonography. At the present time, dual energy (DEXA) is the most common employed method. While there are numerous independent risk factors associated with the development of primary osteoporosis, nearly one-third to one-half of all post-menopausal women are affected. Therefore, age and sex must be considered the most compelling risk factors. Routine screening in otherwise healthy patients is not of benefit in detection and treatment of osteoporosis. Bone mineral density is widely used to guide initiation of treatment of osteoporosis, and to monitor response to therapy. Because of the slow changes in bone mineral density and the precision of measuring technologies, specifically DEXA, monitoring response to therapy prior to two years is unlikely to detect changes. In addition, changes in bone mineral density at central sites (i.e. hip and spine) are often not reflected by changes in bone mineral density at peripheral sites. However, quantitative ultrasound is useful for assessing risk but not for diagnosing and monitoring of patients. Peripheral or central bone density tests are covered.
Extractions: 1. Tanner, J.M. and R.H. Whitehouse, Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child, 1976. 51(3): p. 170-9. 2. Marshall, W.A. and J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch Dis Child, 1969. 44(235): p. 291-303. 3. Herman-Giddens, M.E., et al., Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics, 1997. 99(4): p. 505-12. 4. Kosho, T., et al., Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. J Clin Endocrinol Metab, 1999. 84(12): p. 4613-21. 5. Rao, E., et al., Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet, 1997. 16(1): p. 54-63. 6. Clement-Jones, M., et al., The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet, 2000. 9(5): p. 695-702. 7. Lee, M., Growth hormone deficiency as the only identifiable cause for primary amenorrhea. J Pediatr Adolesc Gynecol, 2000. 13(2): p. 93.
Extractions: 1. Pettersson F, FriesH, Nillius SJ. Epidemiology of secondary amenrrhea. I. Incidence and prevalent rates. Am J Obstet Gynecol 1973; 117:80-6. 2. Bachman G, Kemmann E. Prevalence of oligmenorrhea and amenorrhea in a college population. Am J Obstet Gynecol 1982; 144:98-102. 3. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment. Drug and Therapetuics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936-41. 4. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53:804. 5. Insler V, Melmed H, Mashiah S, Monselise M, Lunenfeld B, Rabau E. Functional classification of patients selected for gonodotropic therapy. Obstet Gynecol 1968; 32:620-626. 6. Block E. Quantitative morphological investigations of the follicular system in women: variations at different ages. Acta Anat 1952; 14:108. 7. Block E. A quantitative morphological investigation of the follicular system in newborn female infants. Acta Anat 1953; 17:201.
Blackwell Synergy - Cookie Absent The development of primary ovarian failure under chemotherapy is caused by Figure 1 shows the incidence of primary ovarian failure, as reflected by the http://www.blackwell-synergy.com/doi/abs/10.1111/j.1600-0609.2005.00459.x
Extractions: Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.
